Dermata Therapeutics Warrant
DRMAW
3 hedge funds and large institutions have $13.2K invested in Dermata Therapeutics Warrant in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.71% less ownership
Funds ownership: 1.81% → 1.1% (-0.71%)
19% less capital invested
Capital invested by funds: $16.4K → $13.2K (-$3.16K)
40% less funds holding
Funds holding: 5 → 3 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$36 |
| 2 |
AC
Armistice Capital
New York
|
-$14 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
1
Boothbay Fund Management
New York
| $13K | – | – | – |
|
|
TSS
2
Two Sigma Securities
New York
| $231 | +$8 | +358 | +3% |
|
|
3
UBS Group
Zurich,
Switzerland
| $44 | -$36 | -1,525 | -37% |
|
|
AC
4
Armistice Capital
New York
| – | -$14 | -1,354 | Closed |
|
|
5
Bank of America
Charlotte,
North Carolina
| – | -$1 | -100 | Closed |
|
DRMAW Hedge Fund Activity: Q1 2025 in Review
3 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q1 2025, worth a combined $13.2K — down 19% from $16.4K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of DRMAW and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Two Sigma Securities, adding an estimated $8. The largest seller was UBS Group, cutting an estimated $36.
- 3 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q1 2025, down from 5 in Q4 2024.
- Funds reported $13.2K of Dermata Therapeutics Warrant stock for Q1 2025, down 19% quarter-over-quarter.
- 0 funds opened new Dermata Therapeutics Warrant positions in Q1 2025 and 2 closed out, a net change of -2 holders.
- The largest Dermata Therapeutics Warrant buyer in Q1 2025 was Two Sigma Securities, an estimated $8 added.
- The largest Dermata Therapeutics Warrant seller in Q1 2025 was UBS Group, an estimated $36 sold.
Based on aggregated 13F filings for Q1 2025.